
Publications of Markus Morkel
All genres
Journal Article (12)
1.
Journal Article
30 (2), pp. 284 - 286 (2014)
MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 2.
Journal Article
30 (2), pp. 284 - 286 (2014)
MEDIPS: genome wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 3.
Journal Article
30 (2), pp. 284 - 286 (2014)
MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 4.
Journal Article
9 (2), p. e1003250 - e1003250 (2013)
DNA–Methylome Analysis of Mouse Intestinal Adenoma Identifies a Tumour-Specific Signature That Is Partly Conserved in Human Colon Cancer. PLoS Genetics 5.
Journal Article
372 (1), pp. 55 - 67 (2012)
In vivo knockdown of Brachyury results in skeletal defects and urorectal malformations resembling caudal regression syndrome. Developmental Biology 6.
Journal Article
131 (10), pp. 2242 - 2252 (2012)
Wnt and BMP signals control intestinal adenoma cell fates. International Journal of Cancer 7.
Journal Article
6 (8), p. e23381 - e23381 (2011)
An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression. PLoS ONE 8.
Journal Article
6 (12), p. e1001231 - e1001231 (2010)
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway dependent gene signatures in colorectal cancer cells. PLoS Genetics 9.
Journal Article
8 (5), pp. 571 - 580 (2010)
A Flexible Multiwell Format for Immunofluorescence Screening Microscopy of Small-Molecule Inhibitors. Assay and Drug Development Technologies. 10.
Journal Article
38 (11), p. e122 - e122 (2010)
An inducible RNA interference system for the functional dissection of mouse embryogenesis. Nucleic Acids Research 11.
Journal Article
177 (1), pp. 151 - 162 (2007)
c-Met is essential for wound healing in the skin. The Journal of Cell Biology: JCB 12.
Journal Article
A colorectal cancer expression profile that includes transforming growth factor ß inhibitor BAMBI predicts metastatic potential.